Analyst Consensus ?
ConsensusHold22 ratings
Bullish1045.5%
Neutral1150.0%
Bearish14.5%
DaVita Inc. · DVA · FY2026 Q3 · Calendar Q4 2026
DaVita’s expanded HD rollout and IKC progress support a narrowed outlook
DaVita’s Q3 results support a constructive operating thesis: clinical progress from expanded HD, mortality-driven census growth, and stronger-than-expected Integrated Kidney Care are potential earnings supports. The evidence is balanced by a narrowed full-year outlook, cost pressure, commercial-mix headwinds, and reimbursement uncertainty.
Reported After market closeNYSEHealthcare
$12.33B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$3.82
Consensus $3.57
EPS surprise
+7.0%
Reported versus consensus
Reported revenue
$3.58B
Consensus $3.52B
Revenue surprise
+1.7%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-6.8%
Event window
SPY move
-1.4%
Same window
Abnormal move
-5.3%
Stock minus SPY
Volume
0.8×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
DVASPY benchmark
Ask FN2 about DVA FY2026 Q3
Transcript, numbers and history already loaded
Why did DVA fall 6.8% after beating EPS estimates in FY2026 Q3?What changed in DVA's guidance and outlook in FY2026 Q3?Give me the bull and bear case for DVA after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported Q3 adjusted operating income of $561 million and EPS of $3.82. Expanded HD showed strong early clinical feedback, with a 10% improvement in treatments achieving optimal fluid removal, while IKC exceeded expectations. The company moved from prior-quarter guidance reaffirmation to a narrowed FY2026 range and said technology investment should grow more slowly going forward.
Guidance delta
Management narrowed full-year 2026 guidance to $2.175-$2.25 billion of adjusted operating income and $14.30-$15.20 of adjusted EPS, versus the prior quarter's reaffirmed $2.2 billion adjusted operating income and $14.65 adjusted EPS targets.
Key takeaways
- Expanded HD dialyzer rollout is on schedule after a pilot with more than 90% adoption across 150 centers serving more than 10,000 patients.
- Integrated Kidney Care exceeded expectations and is now expected to generate at least $65 million of adjusted operating income.
- Management cited higher technology and labor costs, ACA-related commercial mix pressure, and uncertainty around CMS and TDAPA changes.
Management priorities
- Complete the national expanded HD dialyzer rollout, targeted for completion by November.
- Scale Integrated Kidney Care through additional contracts, physician engagement, and the Humana partnership.
- Modernize technology platforms while allowing technology-spend growth to decelerate, and continue share repurchases.
Follow DVA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$180Current
$81Low
$191.58Average
$270High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Aug 7, 2026 |
| TD Cowen | Buy | Hold | Upgrade | Aug 7, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Aug 5, 2026 |
| UBS | Buy | Buy | Maintain | Jul 10, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | May 6, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Sep 10, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | May 15, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 23, 2023 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 29, 2021 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 6, 2020 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 24, 2020 |
| JP Morgan | Neutral | Neutral | Maintain | Dec 20, 2019 |
| Raymond James | Market Perform | Outperform | Downgrade | Nov 7, 2019 |
| Baird | Neutral | Neutral | Maintain | Nov 6, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Sep 11, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 4, 2018 |
| Citigroup | Buy | Neutral | Upgrade | Dec 11, 2017 |
| Jefferies | Hold | Buy | Downgrade | Jun 26, 2017 |
| KeyBanc | Hold | Buy | Downgrade | Sep 17, 2014 |
| Atlantic Equities | Overweight | Overweight | Maintain | Oct 10, 2013 |
| Feltl & Co. | Buy | Buy | Maintain | Oct 31, 2012 |
| Bank oferica | Buy | Buy | Maintain | Apr 5, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $180. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $215 | $179.92 | +19.4% | Aug 7, 2026 |
| Raymond James | Analyst unavailable | $220 | $180.67 | +22.2% | Aug 7, 2026 |
| Oppenheimer | Analyst unavailable | $220 | $180.67 | +22.2% | Aug 7, 2026 |
| Deutsche Bank | Pito Chickering | $265 | $185.52 | +47.2% | Aug 5, 2026 |
| Barclays | Andrew Mok | $224 | $227.99 | +24.4% | Aug 5, 2026 |
| Truist Financial | Analyst unavailable | $250 | $235.58 | +38.9% | Jul 14, 2026 |
| UBS | Analyst unavailable | $270 | $229.48 | +50.0% | Jul 10, 2026 |
| Barclays | Analyst unavailable | $218 | $234.31 | +21.1% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $205 | $194.38 | +13.9% | May 8, 2026 |
| Barclays | Andrew Mok | $194 | $193.88 | +7.8% | May 7, 2026 |
| Deutsche Bank | Pito Chickering | $220 | $157.04 | +22.2% | May 6, 2026 |
| Truist Financial | Analyst unavailable | $158 | $144.42 | -12.2% | Feb 5, 2026 |
| UBS | Analyst unavailable | $190 | $134.73 | +5.6% | Feb 4, 2026 |
| Barclays | Analyst unavailable | $158 | $111.19 | -12.2% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $143 | $126.56 | -20.6% | Oct 30, 2025 |
| Truist Financial | David MacDonald | $140 | $123.36 | -22.2% | Oct 14, 2025 |
| Barclays | Andrew Mok | $149 | $127.89 | -17.2% | Oct 9, 2025 |
| Truist Financial | David MacDonald | $148 | $129.54 | -17.8% | Aug 8, 2025 |
| Bernstein | Lisa Bedell Clive | $184 | $142.4 | +2.2% | Feb 21, 2025 |
| Bank of America Securities | Kevin Fischbeck | $145 | $133.53 | -19.4% | Aug 7, 2024 |
| Barclays | Andrew Mok | $150 | $134.45 | -16.7% | May 6, 2024 |
| Barclays | Sarah James | $81 | $70.54 | -55.0% | Oct 31, 2022 |
| UBS | Andrew Mok | $117 | $93.1 | -35.0% | Aug 19, 2022 |
| Truist Financial | David MacDonald | $90 | $79.44 | -50.0% | Jun 28, 2022 |
Track every rating change on DVA the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationDaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities.…
Historical context
All DVA earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +12.3% | Regeneron: Core Brands Grow as Pipeline Milestones Advance |
| ILMN Illumina, Inc. | FY2026 Q3 · Calendar Q4 2026 | +19.1% | -16.8% | Illumina raises FY2026 outlook as clinical sequencing demand holds up |
| SYK Stryker Corporation | FY2026 Q3 · Calendar Q4 2026 | -0.8% | -5.0% | Stryker cuts guidance as hip and knee demand slows |
| DXCM DexCom, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.1% | +5.6% | Dexcom raises 2026 outlook as G7 15-Day adoption expands |
| ALNY Alnylam Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +879.5% | -25.1% | Alnylam Q3: AMVUTTRA growth meets reimbursement uncertainty |
| KYMR Kymera Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | -4.8% | +0.1% | Kymera advances KT-621 and KT-579 while reaffirming runway |
Latest beats and misses
Who reports nextBeat on EPS
- MSTRFY2026 Q3 · October 29, 2026+121.6% EPS-6.3% move
- EIXFY2026 Q3 · October 29, 2026+3.3% EPS-0.2% move
- STRKFY2026 Q3 · October 29, 2026+121.6% EPS-2.7% move
- RKTFY2026 Q3 · October 29, 2026+10.8% EPS+5.0% move
- ILMNFY2026 Q3 · October 29, 2026+19.1% EPS-16.8% move
- STRCFY2026 Q3 · October 29, 2026+121.6% EPS-1.2% move
Missed on EPS
- SYKFY2026 Q3 · October 29, 2026-0.8% EPS-5.0% move
- DLR-PJFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLRFY2026 Q3 · October 29, 2026-8.4% EPS-3.0% move
- EGFY2026 Q3 · October 28, 2026-18.8% EPS+3.5% move
- MKLFY2026 Q3 · October 28, 2026-2.3% EPS+1.2% move
- KYMRFY2026 Q3 · October 29, 2026-4.8% EPS+0.1% move
Get the DVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T14:07:28.112729+00:00
- FN2 earnings calendar · 2026-10-30T01:23:13.979536+00:00
- Polygon adjusted daily market bars · 2026-10-30T14:50:43.928851+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-30T14:50:43.926247+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-30. For educational purposes only; not investment advice.